MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

February 19, 2014

Doctors Without Borders/Médecins Sans Frontières (MSF) has been treating prisoners and ex-prisoners for drug-resistant tuberculosis (DR-TB) in the Donetsk region of Ukraine since June 2012. In this interview, MSF Field Coordinator Paola Mermati, discusses the challenges faced by the MSF team—and by their patients.

How are these patients different from others?

February 19, 2014

Doctors Without Borders/Médecins Sans Frontières (MSF) has been treating prisoners and ex-prisoners for drug-resistant tuberculosis (DR-TB) in the Donetsk region of Ukraine since June 2012.

March 07, 2013

Ukrainian prisons are a hotbed for the disease, with prevalence rates more than ten times higher than in the rest of society.

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

February 19, 2014

Doctors Without Borders/Médecins Sans Frontières (MSF) has been treating prisoners and ex-prisoners for drug-resistant tuberculosis (DR-TB) in the Donetsk region of Ukraine since June 2012. In this interview, MSF Field Coordinator Paola Mermati, discusses the challenges faced by the MSF team—and by their patients.

How are these patients different from others?

February 19, 2014

Doctors Without Borders/Médecins Sans Frontières (MSF) has been treating prisoners and ex-prisoners for drug-resistant tuberculosis (DR-TB) in the Donetsk region of Ukraine since June 2012.

March 07, 2013

Ukrainian prisons are a hotbed for the disease, with prevalence rates more than ten times higher than in the rest of society.